Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(15):1024-1026; doi:10.1093/jnci/djj321
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McGuire, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, W. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

Is It Time for Some New Approaches for Treating Advanced Ovarian Cancer?

William P. McGuire

Correspondence to: William P. McGuire, MD, Weinberg Cancer Institute, Franklin Square Hospital Center, 9103 Franklin Square Dr., Ste. 2200, Baltimore, MD 21237 (e-mail: william.mcguire@medstar.net).

The first 10% of the full text of this article appears below.

Advanced ovarian cancer is considered to be relatively sensitive to cytotoxic agents and is usually described in medical textbooks as a solid tumor with the potential for cure by chemotherapy. Over the past two decades, the survivorship of patients with ovarian cancer has increased, even though only fewer than 40% of all ovarian cancer patients are cured. Because attempts to develop methods for effective early diagnosis of ovarian cancer have eluded investigators, any increase in long-term survivorship must reflect either more aggressive surgical cytoreduction or more effective therapy. The development of platinum-based combination therapies in the 1980s, in conjunction with expansion of training programs in gynecologic oncology to improve primary surgery, led to data suggesting that the survival rates for ovarian cancer patients would increase (1). With the introduction of the taxanes in the 1990s and their incorporation into primary chemotherapy came . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Find additional patient-related information at:

Third Chemo Drug No Help for Ovarian Cancer


This article has been cited by other articles:


Home page
 Ann OncolHome page
A Gondos, B Holleczek, V Arndt, C Stegmaier, H Ziegler, and H Brenner
Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?
Ann. Onc., July 1, 2007; 18(7): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Mullen, D. A. Cameron, M. Hasmann, J. F. Smyth, and S. P. Langdon
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Mol. Cancer Ther., January 1, 2007; 6(1): 93 - 100.
[Abstract] [Full Text] [PDF]